Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' ARVANITIS LA' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 23 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. McConville, BJ; Arvanitis, LA; Thyrum, PT; Yeh, C; Wilkinson, LA; Chaney, RO; Foster, KD; Sorter, MT; Friedman, LM; Brown, KL; Heubi, JE
      Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders

      JOURNAL OF CLINICAL PSYCHIATRY
    2. McManus, DQ; Arvanitis, LA; Kowalcyk, BB
      Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders

      JOURNAL OF CLINICAL PSYCHIATRY
    3. HONG WW; RAK IW; CIURYLA VT; WILSON AM; KYLSTRA JW; MELTZER HY; CARPENTER WT; LEHMAN A; ARVANITIS LA
      MEDICAL-CLAIMS DATABASES IN THE DESIGN OF A HEALTH-OUTCOMES COMPARISON OF QUETIAPINE (SEROQUEL) AND USUAL-CARE ANTIPSYCHOTIC MEDICATION

      Schizophrenia research
    4. ARVANITIS LA; RAK IW
      THE LONG-TERM EFFICACY AND SAFETY OF SEROQUEL (QUETIAPINE)

      Schizophrenia research
    5. ARVANITIS LA; RAK IW
      EFFICACY, SAFETY AND TOLERABILITY OF SEROQUEL (QUETIAPINE) IN ELDERLYSUBJECTS WITH PSYCHOTIC DISORDERS

      Schizophrenia research
    6. GOLDSTEIN JM; ARVANITIS LA
      SEROQUEL (QUETIAPINE), A PROMISING NEW ANTIPSYCHOTIC AGENT - OVERVIEWOF SAFETY AND TOLERABILITY

      Schizophrenia research
    7. GOLDSTEIN JM; ARVANITIS LA
      SEROQUEL (QUETIAPINE) IS NOT ASSOCIATED WITH DOSE-RELATED EXTRAPYRAMIDAL SYMPTOMS - OVERVIEW OF CLINICAL-RESULTS

      Schizophrenia research
    8. RAK IW; ARVANITIS LA
      OVERVIEW OF THE EFFICACY OF SEROQUEL (QUETIAPINE)

      Schizophrenia research
    9. CANTILLON M; ARVANITIS LA
      CLINICAL-EXPERIENCE WITH QUETIAPINE, AN ATYPICAL ANTIPSYCHOTIC AGENT

      Psychopharmacology bulletin
    10. TARGUM SD; ARVANITIS LA
      QUETIAPINE - EFFICACY, SAFETY, AND TOLERABILITY IN ELDERLY SUBJECTS WITH PSYCHOTIC DISORDERS

      Psychopharmacology bulletin
    11. MCMANUS DQ; RAK IW; ARVANITIS LA
      SAFETY AND TOLERABILITY OF SEROQUEL(R)(QUETIAPINE) IN ELDERLY SUBJECTS WITH PSYCHOSIS

      Neurology
    12. ARVANITIS LA; MILLER BG; BORISON RL; PITTS WM; SHARIF ZA; HAMNER MB; HERZ MI; TRUE JE; VELLIGAN D; KNESEVICH MA; SMALL J; STEINBOOK R; HERTZMAN M; KECK PE; NEWCOMER JW; GRACE J; ROTROSEN J; TANDON R; DOTT SG; FERGUSON JM; ADDINGTON DEN; MACEWAN GW; NAIR VNP; SHRIQUI CL; WILLIAMS R; DANIEL DG; SHEHI GM; PATTERSON WM; MERIDETH CH
      MULTIPLE FIXED DOSES OF SEROQUEL (QUETIAPINE) IN PATIENTS WITH ACUTE EXACERBATION OF SCHIZOPHRENIA - A COMPARISON WITH HALOPERIDOL AND PLACEBO

      Biological psychiatry
    13. SMALL JG; HIRSCH SR; ARVANITIS LA; MILLER BG; LINK CGG; MURPHY AL; BOWDEN CL; OBRIEN CP; STEINBOOK RM; WAGNER RL; PITTS WM; CRABTREE B; CORRIGAN MHN; LOHR JB; MILLER AL; ERESHEFSKY L; ANDERSON CB; KNESEVICH MA; ROTROSEN J; OWEN RR; KARSON CN; LINDENMAYER JP; PFEFFERBAUM A; FAUSTMAN WO; KECK PE; PATTERSON WM; RIESENBERG RA; GLADSON MB; KOLIN IS; BARNES TRE; SENSKY T; RICCIO M; FRANKS S; JOLLEY A; HALLSTROM C; BENNIE E; DARCOURT G; PATRIS M; DESILVA M; PATEL AG; FLEISCHHACKER WW; DIETZEL M; SEIFERTOVA D; VINAR O; FALTUS F; BITTER I; OZSVATH K; SHAW SH; MAHAPATRA SN; SZULECKA TK; SUNDARARAJAN K; CREAVEN F; LYNCH J; KLIESER E; COOPER SJ; ASCHAUER H
      QUETIAPINE IN PATIENTS WITH SCHIZOPHRENIA - A HIGH-DOSE AND LOW-DOSE DOUBLE-BLIND COMPARISON WITH PLACEBO

      Archives of general psychiatry
    14. BORISON RL; ARVANITIS LA; MILLER BG
      A COMPARISON OF 5 FIXED DOSES OF SEROQUEL (ICI-204,636) WITH HALOPERIDOL AND PLACEBO IN PATIENTS WITH SCHIZOPHRENIA

      Schizophrenia research
    15. BORISON RL; ARVANITIS LA; MILLER BG; ALPHS LD; CARMAN JS; DIAMOND B; GEWIRTZ G; HAMNER MB; HIRSHFIELD R; MCEVOY JP; MUKHERJEE S; NASRALLAH HA; OXENKRUG G; RYAN W; SMITH N; TAMMINGA C
      ICI-204,636, AN ATYPICAL ANTIPSYCHOTIC - EFFICACY AND SAFETY IN A MULTICENTER, PLACEBO-CONTROLLED TRIAL IN PATIENTS WITH SCHIZOPHRENIA

      Journal of clinical psychopharmacology
    16. ARVANITIS LA; MILLER BG
      ICI-204,636, AN ATYPICAL ANTIPSYCHOTIC RESULTS FROM A MULTIPLE FIXED-DOSE, PLACEBO-CONTROLLED TRIAL

      Psychopharmacology bulletin
    17. HONG WW; ARVANITIS LA; MILLER BG; LINK CGG
      THE ATYPICAL PROFILE OF ICI-204,636 IS SUPPORTED BY ITS LACK OF INDUCTION OF EXTRAPYRAMIDAL SYMPTOMS

      Psychopharmacology bulletin
    18. HAMNER MB; ARVANITIS LA; MILLER BG; LINK CGG; HONG WW
      PLASMA PROLACTIN IN SCHIZOPHRENIA SUBJECTS TREATED WITH SEROQUEL(TM) (ICI-204,636)

      Psychopharmacology bulletin
    19. HIRSCH SR; LINK CGG; GOLDSTEIN JM; ARVANITIS LA
      ICI-204,636 - A NEW ATYPICAL ANTIPSYCHOTIC DRUG

      British Journal of Psychiatry
    20. BORISON RL; ARVANITIS LA; MILLER BG
      A MULTIPLE FIXED-DOSE, PLACEBO-CONTROLLED TRIAL WITH SEROQUEL - AN ATYPICAL ANTIPSYCHOTIC

      Biological psychiatry
    21. HONG WW; ARVANITIS LA; MILLER BG
      SEROQUEL (ICI-204,636) - NOT DIFFERENT FROM PLACEBO FOR EPS OF PROLACTIN

      Biological psychiatry
    22. BORISON RL; ARVANITIS LA; MILLER BG; LINK CGG; HONG WW
      SEROQUEL (ICI-204,636) - A NOVEL, ATYPICAL ANTIPSYCHOTIC

      Biological psychiatry
    23. HAMNER MB; ARVANITIS LA; MILLER BG; LINK C; HONG WW
      THE EFFECTS OF SEROQUEL (ICI-204.636) ON PLASMA PROLACTIN IN PATIENTSWITH SCHIZOPHRENIA

      Biological psychiatry


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 17/01/21 alle ore 22:22:54